LDL cholesterol and uridine levels in blood are potential nutritional biomarkers for clinical progression in Alzheimer's disease: The NUDAD project. Issue 1 (30th December 2020)

• Record Type: Journal Article
• Authors: de Leeuw, Francisca A.; Tijms, Betty M.; Doorduijn, Astrid S.; Hendriksen, Heleen M. A.; van de Rest, Ondine; de van der Schueren, Marian A. E.; Visser, Marjolein; van den Heuvel, Ellen G. H. M.; van Wijk, Nick; Bierau, Jörgen; van Berckel, Bart N.; Scheltens, Philip; Kester, Maartje I.; van der Flier, Wiesje M.; Teunissen, Charlotte E.
• Is Part Of: Alzheimer's & dementia. Volume 12:Issue 1(2020)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2020-12-30
• Subjects: Alzheimer's disease -- cholesterol -- clinical progression -- memory clinic -- nutritional biomarkers -- uridine; Alzheimer's disease -- Periodicals; Alzheimer's disease -- Diagnosis -- Periodicals; Dementia -- Periodicals; Dementia -- Diagnosis -- Periodicals; 616.831
• DOI: 10.1002/dad2.12120
• Languages: English
• ISSNs: 2352-8729

Abstract

Abstract: INTRODUCTION: We examined associations between nutritional biomarkers and clinical progression in individuals with subjective cognitive decline (SCD), mild cognitive impairment (MCI), and Alzheimer's disease (AD)‐type dementia. METHODS: We included 528 individuals (64 ± 8 years, 46% F, follow‐up 2.1 ± 0.87 years) with SCD (n = 204), MCI (n = 130), and AD (n = 194). Baseline levels of cholesterol, triglycerides, glucose, homocysteine, folate, vitamin A, B12, E and uridine were measured in blood and S‐adenosylmethionine and S‐adenosylhomocysteine in cerebrospinal fluid. We determined associations between nutritional biomarkers and clinical progression using Cox proportional hazard models. RESULTS: Twenty‐two (11%) patients with SCD, 45 (35%) patients with MCI, and 100 (52%) patients with AD showed clinical progression. In SCD, higher levels of low‐density lipoprotein (LDL) cholesterol were associated with progression (hazard ratio [HR] [95% confidence interval (CI)] 1.88 [1.04 to 3.41]). In AD, lower uridine levels were associated with progression (0.79 [0.63 to 0.99]). DISCUSSION: Our findings suggest that LDL cholesterol and uridine play a—stage‐dependent—role in the clinical progression of AD.